B
BMRN icon

Barings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Barings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,104
Closed -$204K – 686
2018
Q3 		$204K Sell
2,104
-1,736
-45% -$173K ﹤0.01% 756
2018
Q2 		$362K Hold
3,840
– – 0.01% 719
2018
Q1 		$311K Hold
3,840
– – ﹤0.01% 802
2017
Q4 		$343K Buy
+3,840
New +$334K ﹤0.01% 803
2013
Q4 		– Sell
-3,200
Closed -$231K – 917
2013
Q3 		$231K Buy
+3,200
New +$213K 0.01% 841

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barings's BMRN Position: Q4 2018 in Review

Barings sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 2,104 shares — an estimated $204K sold.

Barings first reported a position in BMRN in Q3 2013 and held it in 5 quarters. The position peaked at $362K in Q2 2018. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

  • Barings reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Barings sold 2,104 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $204K.
  • Barings first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Barings's BioMarin Pharmaceuticals position peaked at $362K in Q2 2018.
  • 473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Barings's 13F filing for Q4 2018, filed 7 Feb 2019.